Self-Administered Parenteral Market Share, Trend Analysis, Key Drivers, Size And Forecast To 2033

The new report published by The Business Research Company, titled "" Self-Administered Parenteral Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the self-administered parenteral market size has grown strongly in recent years. It will grow from $23.14 billion in 2023 to $24.57 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The self-administered parenteral market size is expected to see steady growth in the next few years. It will grow to $29.8 billion in 2028 at a compound annual growth rate (CAGR) of 4.9%.

Download Free Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=13927&type=smp

Chronic Diseases Fueling Self-Administered Parenteral Market Expansion
The growing incidence of chronic diseases is expected to propel the growth of the self-administered parenteral market going forward. Chronic diseases are long-lasting medical conditions that generally progress slowly over time and often require ongoing management and treatment. Self-administered parenteral products are used in the management of chronic diseases to manage treatment independently, which can significantly improve adherence compared to oral medication. For instance, in January 2023, according to the National Institutes of Health, a US-based government agency, among the population aged 50 or above, the number of people with at least one chronic disease is expected to increase by 99.5% from 71.522 million in 2020 to 142.66 million by 2050. Therefore, the growing incidence of chronic diseases is driving the growth of the self-administered parenteral market.

Innovative Autoinjector Solutions Revolutionizing the Self-Administered Parenteral Market
Major companies operating in the self-administered parenteral market are focusing on developing innovative products, such as the UDENYCA autoinjector, to provide increased choice and control, ultimately making treatment more accessible to patients. An autoinjector is a medical device designed to deliver a single dose of a particular drug. It is an intuitive design with administration triggered immediately and reliably by push-on-skin activation. For instance, in May 2023, Coherus BioSciences Inc., a US-based biotech company, launched the UDENYCA autoinjector, a self-administered parenteral medication in the US. The UDENYCA Autoinjector is a single-dose, prefilled autoinjector that offers patients an additional administration option for pegfilgrastim. It is designed to be intuitive, with administration triggered by push-on-skin activation, allowing for reliable and immediate delivery of a full pegfilgrastim dose. Additionally, it offers several user-friendly features that promote successful delivery, including fast dosing, intuitive design, dual coverage, at-home and in-office use, and a reduction of febrile neutropenia risk.

The self-administered parenteral market covered in this report is segmented -

1) By Product: Pre-Filled Syringes, Autoinjectors, Pen Injectors, Other Products
2) By Usage: Disposable, Reusable
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Home Healthcare Providers, Specialty Clinics, Other Distribution Channels
4) By Application: Cardiovascular Diseases, Diabetes, Osteoporosis, Pain Management, Hormone Replacement, Other Applications

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=13927&type=discount

Major companies operating in the self-administered parenteral market report are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi S.A., AstraZeneca PLC, Roche Holding AG, Eli Lilly and Company, Novo Nordisk A/S, Becton, Dickinson and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Terumo Corporation, Catalent Inc., Dexcom Inc., West Pharmaceutical Services Inc., Gerresheimer AG, Biocon Limited, Insulet Corporation, Halozyme Therapeutics Inc., Ypsomed AG, Antares Pharma Inc., SHL Medical AG, Owen Mumford Ltd., Novartis AG, Kaleo Inc., Haselmeier AG, Bespak (A Consort Medical Company), Senseonics Holdings Inc., ScPharmaceuticals Inc., Fresenius Kabi AG

Contents of the report:
1. Executive Summary
2. Self-Administered Parenteral Market Report Structure
3. Self-Administered Parenteral Market Trends And Strategies
4. Self-Administered Parenteral Market - Macro Economic Scenario
5. Self-Administered Parenteral Market Size And Growth
…..
27. Self-Administered Parenteral Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @ https://www.thebusinessresearchcompany.com/report/self-administered-parenteral-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.